NEWARK, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) and genOway (NYSE:ALGEN) announced today that they have entered into a license agreement under which StemCells has granted genOway a worldwide, exclusive license to StemCells’ Internal Ribosome Entry Site (IRES) technology for use in the development and commercialization of genetically engineered mice. Financial conditions were not disclosed.
